Corporate Presentation

CEO, Aaron BensimonCFO, Frédéric Tarbouriech

This document has been prepared by Genomic Vision (the "Company") and is provided for information purposes only. This document does not purport tocontain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that theCompany is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris. No reliance maybe placed for any purposes whatsoever on the information or opinions contained in this document or on its accuracy or completeness This presentationdoes not constitute an offer to sell, a solicitation of, or an invitation to subscribe for or to buy, securities of Genomic Vision in any jurisdiction.

The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised,verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the informationor opinions contained herein which are subject to change without prior notice.

The information contained in this document has not been subject to independent verification. No representation, warranty or undertaking, express orimplied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, itssubsidiaries, its advisors and representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage thatmay arise from the use of this document or the information or opinions contained herein.

This document contains information on the Company’s markets and competitive position, and more specifically, on the size of its markets. Thisinformation has been drawn from various sources or from the Company’s own estimates which may not be accurate and thus no reliance should beplaced on such information.

This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts andestimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future eventsand are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, beconstrued as a guarantee of the Company's future performance and the Company’s actual financial position, results and cash flow, as well as the trends inthe sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in thisdocument. Important factors that could cause actual results to differ materially from the results anticipated in the forward looking statements includethose discussed or identified in the “Risk Factors” section of our Base Document registered with the Autorité des marchés financiers on March 3, 2014under number I.14-005 (a copy of which is available on www.genomicvision.com). Even if the Company’s financial position, results, cash-flows anddevelopments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such resultsor developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake anyobligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order toreflect an event or circumstance that may occur after the date of this document. Certain figures and numbers appearing in this document have beenrounded. Consequently, the total amounts and percentages appearing in the tables may not necessarily equal the sum of the individually rounded figures,amounts or percentages. All persons accessing this document must agree to the restrictions and limitations set out above.

Forward looking statement

2

• Commercial-stage Molecular DX company developing and selling tests and assays on Molecular Combing platform for:

- In Vitro diagnostics (IVD) for genetic diseases and cancers

- Life Sciences Research (LSR)

• Proprietary technology enabling direct visualization ofhigh molecular weight DNA moleculesUnique position to address both:

- Structural Genomics (GMC)

- Functional Genomics: DNA replication

• Multiple value-creation milestones:

- Promising pipelines in IVD (HPV, SMA)

- Adoption of Replicome in Pharma especially for novel therapeutic discovery & development in immuno-oncology

- Novel tool for Gene Engineering optimization and safety tool

Genomic Vision at a glance

3

Co-development agreement with the Assistance Publique -

Hôpitaux de Marseille 2006

CombHeliX FSHD test CE marked

2013

Strategic alliance with Quest Diagnostics

2010

Renewal of alliance with QD until 2018

2015CombHeliX FSHD test commercialized in US

and EU2013

IPO on Euronext Paris, €25.8m raised

2014

Company was created as a spin-off from Institut

Pasteur2004

From breakthrough innovation to commercialization

Product & Services Offering for LSR market

2016

Technological collaboration with

AstraZeneca2017

4

14 patented portfolios2 co-patented portfolios6 patented portfolios licensed from Pasteur

Direct visualization of high molecular weight DNA molecules

Vinyl-silane coated glass surface immersed in a solution of extracted DNA

DNA molecules adsorbed and stretched uniformly over the glass surface in parallel strands

Hundreds of copies of a human sample genome allowing quantitative analysis

The process of stretching DNA on a substrate by the action of an air/liquid interface

• No prior amplification

• Uniform and constant stretching factor (2kb=1µm), irrespective of DNA molecule size

• Stretching independent of sequence content

• Hundreds of copies of a diploid human genome stretched on one surface

DNA DNA combing automatized with GV equipment FiberComb

5

Direct visualization of 3kbp–1Mbp DNA

6

NGS (Sequencing) misses Structural Variations (SV) that drive biology and pathology

Point Mutations Structural Variations and Copy Number Variations

Chromosomic aberrations

1bp - 2kbp 3 kbp – 1Mbp 2Mbp - Gbp

Sequencing FISH

ATGC ATCC

MOLECULAR COMBING

Dire

ct

visu

aliz

atio

nRe

gion

s of

in

tere

st

The gene and its environment

GV unique technology enables to visualize Structural Variations anddynamic genomic events (Copy Number Variations)

Genomic Vision’s competitive environment

Source: Genomic Vision;.

Long Read Sequencing

FISH

Molecular combing, Digital count and Nanochannel

Direct detection

Structural Variations and Copy number variations

Chromosomal aberrations

PCR and NGS

Indirect detection (fragmentation

and amplification)

CGH and MLPA

Small mutations

7

GV is well positioned in the Structural Variations and Copy Number Variations segments, with a relatively low number of competitors

Workflow and Product offering (sales & services)

Extraction Hybridisation /Label Detection

Imageacquisition GMC analysis

1 2 3 4 5

Combing

FiberPrep®

DNA Extraction Kit

FiberProbes®

Genomic Morse Code

set

FiberVision®

Automated high

throuput Scanner

FiberStudio®

Analysis Software

Report

FiberComb®

Molecular Combing

System

In progress in 2017 development of new products offering

8

Products & Services

GV’s products & services address the life science continuum

In Vitro Diagnostic (IVD)

Products

• Genetic testing for hereditary diseases and cancers:– Diagnostic– Predisposition– Carrier screening– Screening

Life Sciences Research (LSR)

Biopharma, Industry, Academic labs

• Research tools with combing• Discovery tool, biomarkers identification• DNA replication, damage and repair assays

Academic research

Drug Discovery

Clinical Diagnostics

Gene Editing

1 2 3 4

Hospitals, Reference labs

9

Diversified assay pipeline with near-term value creation Life Sciences Tools (LST)

RCA

GMC

Product design Product development

Research lab collaboration

IndustrializationCommercial launch

GE

2016

Jan 2017

Expected Q4 17

In Vitro Diagnostic (IVD)Identification of targets/gene biomarkers

Development Clinical evaluation Commercial launch

FSHD

BRCA

HNPCC

HPV*

SMA

2013

Commercial launch depending on Quest decision pending clinical study results

Clinical study on-going for validating biomarker

*Screening test not covered by North America exclusivity rights granted to Quest Diagnostic

Biomarker validation expected in 2017

Several new assays/applications under development: Fragmentation assay, Telomere length assay, Resection assay

10

UV+ CT

À terminer

• Immocytochemistry

- Global average analysis

• Fiber Spreading

- Discrete counting of molecular events- Approximate measurement of events

• Molecular Combing

- Discrete counting of molecular events- Reliable measurement of kinetics- High sensitivity

A novel tool for measuring DNA dynamicsTechnical added-value & robustness of GV technology

*Svetlova et al.,Experimental Cell Research 276, (2002) – **MRC LMB Lab website (UK)

*

**

11

• Precise measurement of DNA replication kinetics, origin counting• Evaluation of repair capacity (NER system)

Fundamental studies, knock-out models, drug development, therapy response, genotoxicity

A novel tool for measuring DNA dynamicsReplication and Repair assays

DNA Replication Combing Assay (RCA) Nucleotide Excision Repair Combing Assay (NERCA)

UDS signals

12

• Validate the planned gene editing event – deletion, insertion

• Detect incorrect events larger than 1kb – incorrect deletion, insertion, inversion

• Quantify Off-target / On-target Ratio

A novel tool for Genome Editing

13

Molecular Combing

Modified Genomes

Quality control

Delivered DNA fragment

Genome

Cas 9

Tailor-made GMC provides a powerful quality control tool for high-confidence gene editing

Normal signals [No deletion]

Gene-edited signals [Deletion]

Replication kinetics

• Unique technology enabling to analyze replication kinetics of molecules

• Potential for discovery of novel drug

Growing interest from pharma, biotechs and gene editing companies

Rationale Collaboration

• Technological collaboration in the field of targeting DNA damage response (DDR) for novel anti-cancer treatments strategy.

• Initiated in Q2’17 with platform installed at AZ Cambridge Genetic Center

• Under exploration

Emerging markets at the heart of the future precision medicine

Safety tool

• Enabling to check by high sensitivity & unbiased direct visualization:

- On-target stability

- Rare off-target translocation

Astra Zeneca

Phar

ma

Gen

e Ed

iting

14

FiberVision®

Hardware/Software

Consumables Serv

ices

LeLab

FiberStudio®FiberComb®

FiberPrep® FiberProbes®Accessories

GMC On Demand EasyScan

R&D services Customer support

Key Partnerships & Targeted Commercial Deals

Generate OpportunitiesFeed Product Innovation

15

Commercial strategy in Life Sciences Research

SMA combing test: improvement of the genetic counselling by identifying a sub-population of SMA carriers

16

Genomic Vision’s objectives:

- Identification by Molecular Combing of a biomarker associated with the “2+0” structural variation

- Development of a clinical diagnostics test to identify “2+0” carriers

Spinal Muscular Atrophy • Autosomal recessive disorder due to homozygous loss of functional SMN1 protein

• 1 million to 1.5 million healthy carriers in Franc, 8% of them going undetected by tests currently available

• 2nd most frequent neuromuscular child disease after Duchenne with incidence of 1/6,000 - 1/10,000 births

International partnerships and entry into clinical development

- The SMN locus, poorly characterized by sequencing, was precisely mapped by molecular combing

- BADGES study (NCT02550691) in collaboration with the Rouen University Hospital

- A Pilot study with Quest Diagnostics with samples from African-American cohort

- Participation in ‘BeyondSeq’, a European’s Commission project within the framework of the Horizon 2020 program

Centromeric copy Telomeric copy

SMN2

SMN1

500Kb 500Kb

CNV

ROUTINE PAP-SMEAR

Pos

Wait 1 yearRedo pap-smear COLPOSCOPY

Clear cutresults

Ambiguous results

HPV TestHPV +

NegHPV Combing

Test

HPV -50% 50%

HPV Combing test to avoid invasive and expensive colposcopies

- Detection of HPV integration

- Distinguishes high-or low-risk patients

- Avoids useless invasive colposcopies

Cervical cancer

• Cervical cancer is the third most common cancer among women

• Almost 100% of patients with cervical cancer are positive for HPV

• 90% are transient, the persistence is usually accompanied by the integration of the HPV

50% of women tested positive with a conventional HPV test do not require colposcopy

HPV tests

Nb. of colposcopies per year

56.3 million

4.1 million

67.5 million

3.4 million

ESTIMATED SCREENING MARKET

HPV clinical study underway

- Clinical study started at Reims University Hospital to Establish New Screening Tool for Early Detection and Prevention of Cervical Cancer

- In parallel, Clinical study on-going in Prague with PCS CRO: interim promising results disclosed in May 2017

17

HPV combing test: a “game changer” and unpartnered asset

BRCA combing test: a potential blockbuster for BRCA large rearrangements detection

- Test validation by Quest Diagnostics in 2015

- Clinical utility and positioning study in Europe and the USA to support marketing and reimbursement of the test ongoing (BRCA1000 study jointly performed with Quest Diagnostics)

Test development on-going

• 5% - 10% of breast cancer cases are familial inherited

• HBOC risk increases dramatically in the presence of mutations in BRCA1 and BRCA 2 genes

• 10% - 15% of BRCA mutations are Large Rearrangements (LR)

Hereditary Breast and Ovarian Cancer (HBOC)

Detection of point mutations in BRCA genes by sequencing

Detection of LR in BRCA genes

Patients and people with strong family historyBRCA combing test enables detecting new LR in BRCA genes

BRCA combing test added values:

- Detection of all balanced rearrangements

- Covers exon and non-coding regions

- Accurate visualization hard to sequence regions

Molecular Combing

18

Initial R&D funding1

• Payment to GV of R&D milestones

• Development of lab-developed tests (LDTs) used by Quest

Commercial license2

• An exclusive license for commercializing in the US:

– FSHD test: launched in August 2013

– BRCA test (clinical study ongoing)

– HNPCC test (pending QD)

– SMA (clinical study to be completed in 2018)

• High teens royalties

Equity investment3

• 13.8% stake in Genomic Vision

• 1 Board member

• Strategic alliance with Quest Diagnostic since 2010, renewed in 2015 for 3 additional years until November 2018

• Strong interest expressed by Quest Diagnostics management for the unique combing platform developed by GV to enable discovering new products and offering better services to patients

Strategic U.S. partnership with Quest Diagnostics

19

Description partnership Quest’s Background

• US leading provider in clinical diagnostic (24% market share)

• Annual revenues of approx. $7,5 billion

Academic Combing Community Collaborations expansion

Increasing adoption of combing: 112 FiberComb installed base in 2016

Example of Key Academics using GV combing technology (non-exhaustive):

20

Expanded commercial footprint

LSR Direct sales force (US & Europe) and distribution contract established for China

Global Pharma and Gene Editing collaborations

IVD strategic partnership in the US with Quest Diagnostics

e-Commerce Web site launch in Q2 2017

21

2017 business update and outlook

- Combicoverslips®

- FiberPrep®

- Fiberprobes®

- Reservoir- Carriers

- FiberComb®

- FiberVision®

GV Business Model: multiple revenue streams

23

Hardware & software sales

Consumable sales Royalties

- Distributors - Development

partners

Services & design sales

- EasyScan®

- EasyComb®

- GMC On Demand

• Full-year 2016 sales of products and services up 346% to €1.2 million:

- strong growth momentum in both LSR and IVD markets in the second half of 2016 - installed platform base x2

• Sales of products and services up 141% to €0.7 million in H1 2017 thanks to strong trends in LSR market in Q2 after no sales of platform in Q1 as budgeted due to seasonal effect.

• Cash position as at June 30, 2017 of €2.9 million compared to €4.7 million as at March 31:

- further potential funding of up to €8.5m in the form of convertible notes with warrants- given cost optimization measures implemented and 2016 tax credit to be cashed-in in Q3’17 for €1.4

million, available funding source offers more than 12 months visibility

H1 / FY 2016: revenue from sales and cash position

24

FY (audited) H1 (reviewed)

In € thousands – IFRS 2016 2015 2017 2016Revenue from R&D Collaboration with Quest Diagnostics 315 2,066 150 154

Sales of Products and Services 1,240 278 657 273of which Life Science Research (LSR) 874 164 590 208of which in-vitro diagnostics (IVD) 366 114 77 62

Total Revenue from Sales 1,555 2,345 817 426

• New commercial structure set up• FiberVision® platform installed based

doubled• Sales quadrupled vs 2015

25

Sales trend and 2017 outlook

GV sales 2014-2016

K€

600

70 131

300

89147

184

160

0

250

500

750

1000

1250

1500

2014 2015 2016

278

1,244

FiberVison

FiberComb

Consumables

Services

159

Sales in k€

CAGR: +171%

• Launch of replicome offering• Worldwide unique position in FSHD

reinforced• US sales force presence increaseed• Expansion in Asia (China)• Partnerships to be considered

2016

2017 growth drivers

2017 target revenues: DOUBLE products & services sales

Several milestones in 2017

New platform and DNA extractors

4

• Launch of new platform tailored for LSR individual labs

Gene Editing safety tool offering

3

• Establishment of the molecular combing GMC as safety tool for designing and executing gene editing

HPV test(screening of cervical

cancer risks given HPV integration)

• Results of clinical study with PCS in Czech and IDAHO in France

2

Replicome adoption by research & pharma labs

• Adoption of the Replication Combing Assay by research & pharma labs for discovery and compounds optimization

1

Partnership

5

• Key partnership with a major Life Science player: global pharma or/and gene editing or/and biotech companies

Genomic Vision - les Sismo

DESIGN FINAL

26

• 12-month high: €7.60 (Sept 26th, 2016)

• 12-month low: €2.6 (April 26th, 2017)

• Number of shares: 4,868,385

• Market Cap: €22.3m (June 5th, 2017)

• Average daily trading: 20,103 shares (over the last 12 months)

Shareholding structure (As of 31.12.2016)Stock market information (source: Euronext)

10,1%

3,6%

13,8%

36,2%

36,1%

0,3%

Management, founders & employees

Institut Pasteur

Quest Diagnostic

Free Float

Vesalius Biocapital

Treasury shares

Genomic Vision en bourse

Coverage

27

Thank youAaron BensimonFounder and CEOGenomic Visiona.bensimon@genomicvision.comTel +33 6 85 83 53 23

Frédéric TarbouriechCFOGenomic Visionf.tarbouriech@genomicvision.comTel +33 1 49 08 07 41